Clinical trials of new selective RAF inhibitors are currently recruiting, and two recent ‘proof of concept’ phase-I studies have shown activity in metastatic melanoma, a disease notoriously resistant to systemic treatment. This evidence concerns the gene RAF1 and metastatic melanoma.